Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 2, Placebo Group Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 15, 2026, 4:22 AM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

NSAIDS Following Elective Lumbar Spine Fusion

NCT07743606
View directory record Official record
Conditions
NSAID (Non-Steroidal Anti-Inflammatory Drug), Lumbar Spine Fusion, Ketorolac, Postoperative Pain
Interventions
Ketorolac, Naproxen, Standard Postoperative Pain Management
Drug · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

NCT05519644
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement
Other · Behavioral · Biological + 1 more
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

NCT03873038
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 15, 2026, 4:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 15, 2026, 4:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use

NCT04659278
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence, Alcohol-Related Disorders
Interventions
Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Placebo, Peppermint Oil, masking flavor
Dietary Supplement · Other
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

NCT00477490
View directory record Official record
Conditions
Nocturia
Interventions
desmopressin acetate, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
70
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 15, 2026, 4:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome

NCT02153983
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Colchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 15, 2026, 4:22 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

NCT04481594
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
HPN-01, Placebo
Drug
Lead sponsor
Hepanova Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

NCT04177355
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 15, 2026, 4:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken

NCT05248737
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
DHA/EPA fortified chicken plus Placebo, non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement, non-DHA bio-enhanced chicken plus supplement DHA Omega-3, 25(OH)D bioenhanced chicken and eggs plus placebo, Dietary Supplement: DHA/EPA fortified eggs plus Placebo, non-DHA bio-enhanced eggs plus supplement DHA Omega-3, non-25(OH)D fortified chicken/eggs plus placebo
Dietary Supplement · Other
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Recruiting Phase 2Phase 3 Interventional

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
JX10, Placebo
Drug
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

NCT01686555
View directory record Official record
Conditions
Lupus Erythematosus
Interventions
ABT-199, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • DeBary, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 15, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

NCT01792635
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

NCT01728220
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Advancing Personalized Antidepressant Treatment Using PET/MRI

NCT02623205
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 15, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

NCT02087241
View directory record Official record
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Computerized Alcohol Misuse Intervention System for Health Care

NCT02368899
View directory record Official record
Conditions
Alcoholism
Interventions
Computerized Alcohol Misuse Intervention, Attention Control (AC)
Other
Lead sponsor
Research Circle Associates, LLC
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 4:22 AM EDT
Recruiting Not applicable Interventional

Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture

NCT06571110
View directory record Official record
Conditions
Fibromyalgia
Interventions
Traditional Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 15, 2026, 4:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 4:22 AM EDT